YOU enters the post-earnings window with momentum the stock hasn't seen in months. Shares closed at $58.77 on Tuesday, up 9.3% on the week and 14.4% over the past month. The company just reported Q1 2026 results on May 6, and the immediate market reaction is making shorts reconsider their positioning.
The shift in analyst sentiment is the most striking development this week. Needham's Joshua Reilly moved his price target from $60 to $70 on the day of the report — a fresh and meaningful upgrade from a firm that has been constructive on the name all year. That target now represents the high end of a fairly dispersed consensus. Targets among active followers span from Wells Fargo's $33 bear perch — where an Underweight rating reflects concerns about declining retention and softening engagement — all the way to DA Davidson's $65, raised in late March. The consensus mean sits around $56, which is now fractionally below Tuesday's close. That means the Street as a whole is running slightly behind the tape. A $5.6 billion market cap at the current price is modest relative to the company's $1.05 billion revenue guidance and 58% EBITDA growth trajectory. The P/E ratio has re-rated to around 28.7x over the past 30 days, up more than 14% from where it stood a month ago.
The bull case rests on compounding scale. Cumulative enrollments reached 38 million members — up 31.5% — and adjusted EBITDA hit $79.9 million in the most recently reported period, well ahead of expectations. Revenue guidance for the full year was lifted to $1.05 billion, reflecting 16.3% growth. Bears push back on one persistent number: the gross dollar retention rate has now declined for five consecutive quarters, reaching 86.4%. Annual CLEAR+ member usage fell 2.7% year-over-year. Enrollment is growing, but engagement and stickiness are moving in the wrong direction. That tension — volume up, intensity down — is the central debate the next quarterly print will need to resolve.
Short positioning adds an interesting layer to this week's price action. At 10.3% of free float, short interest is material enough to make a sustained rally uncomfortable for bears. The short-share count had been unwinding through April — it peaked near 11 million shares in early April before falling to just under 10 million by the start of this week. The May 6 earnings event appears to have nudged shorts slightly higher by 0.8% on the day, suggesting some defensive repositioning rather than a wholesale capitulation. The ORTEX short score of 51.8 reflects a broadly neutral-to-cautious read, well down from the mid-50s seen in mid-April. Cost to borrow remains undemanding at 0.41% APR, down nearly 15% on the week. Borrow availability is loose — the 52-week availability peak reached nearly 49% utilisation at its tightest, but that market stress has fully receded. There is no meaningful squeeze dynamic at current levels.
Options traders have rotated sharply toward calls over the past few weeks. The put/call ratio dropped to 0.80 — well below its 20-day average of 0.94, running nearly 0.8 standard deviations on the bullish side. For context, the PCR sat above 1.17 throughout early-to-mid April, when the stock was trading in the high $40s. The flip from protective to directional positioning neatly tracks the stock's recovery. The 52-week PCR low is 0.0, so there is technically room for more call-heavy skew to develop if the earnings narrative takes hold. For now, options positioning looks opportunistic rather than euphoric.
The insider register offers an ambiguous backdrop. Founder and CEO Caryn Seidman-Becker sold roughly $11.7 million in stock during early March, across multiple tranches near $48–$50. President Michael Barkin sold $1.75 million on April 1. CFO Jennifer Hsu sold a smaller amount on the same date. All three sales came at prices well below Tuesday's close of $58.77. These were pre-planned transactions rather than distressed exits, but the pattern of concentrated selling from senior management into the mid-$40s — while the stock now trades above $58 — will invite scrutiny about whether insiders were too early or whether the rally has run well ahead of fundamentals. The 90-day net share count including awards remains positive at approximately 700,000 shares, softening the directional read somewhat.
The next scheduled earnings event is June 10. Between now and then, the focus narrows to whether the Street revises its consensus targets above the current close, and whether the retention trend — five consecutive quarterly declines — shows any stabilisation in the reported data.
See the live data behind this article on ORTEX.
Open YOU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
